anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The rate of obesity is increasing in the Australian population, and this also includes patients with cancer. The safety and dignity of this cohort of patients is paramount as well as the timely acquisition of equipment required to assist patients with obesity to complete a course of radiation therapy (RT). The design and manufacture of equipment used in most RT departments is not suitable for the weight or BMI of all patients presenting for treatment. RT also operates under a unique set of circumstances that differs from the routine hospital environment which prompted the design of an RT bariatric protocol for use in our department. The protocol is based on the mapping of a patient's pathway from simulation and treatment. Treatment technique and equipment limitations as well as information relating to a patient with high BMI are used as trigger points that direct a patient pathway. The bariatric protocol provides the RT team with decision-making support for appropriate resource utilisation ensuring safe and efficient treatment delivery for both the patient and staff. This paper will outline how the RT bariatric protocol was developed and implemented in our department, highlighting areas that required more attention due to the RT-specific environment.
A pharmaceutical waste disposal assembly (10) for disposing of raw pharmaceutical waste comprises a first receiver body (19) and a first reactive agent (287). The first receiver body (19) receives the pharmaceutical waste. The first receiver body (19) includes a receiver bottom (283). The first reactant (287) is located within the first receiver body (19) and spaced apart from the receiver bottom (283). The pharmaceutical waste reacts with the first reactive agent (287) to modify the pharmaceutical waste by one of chemical and physical means such that the pharmaceutical waste is unrecoverable. The first receiver body (19) may receive fluid pharmaceutical waste and/or solid pharmaceutical waste. The first reactant (287) may include one or more of a denaturant, an emetic and a bittering agent. For example, the first reactant (287) may include one or more of quinine, ipecac, and denatonium benzoate.
A 3-month behavior change intervention i.e. one initial, face-to-face, physical activity counselling and two telephone-assisted counselling.
Signs and symptoms of excessive doses of epoprostenol during clinical trials are the expected dose-limiting pharmacologic effects of epoprostenol, including flushing, headache, hypotension, tachycardia, nausea, vomiting, and diarrhea. Treatment will ordinarily require dose reduction of epoprostenol.

One patient with secondary pulmonary hypertension accidentally received 50 mL of an unspecified concentration of epoprostenol. The patient vomited and became unconscious with an initially unrecordable blood pressure. Epoprostenol was discontinued and the patient regained consciousness within seconds. In clinical practice, fatal occurrences of hypoxemia, hypotension, and respiratory arrest have been reported following overdosage of epoprostenol.

Single intravenous doses of epoprostenol at 10 and 50 mg/kg (2,703 and 27,027 times the recommended acute phase human dose based on body surface area) were lethal to mice and rats, respectively. Symptoms of acute toxicity were hypoactivity, ataxia, loss of righting reflex, deep slow breathing, and hypothermia.
In patients with breast cancer, oncoplastic breast-conserving surgery can achieve a good aesthetic outcome without compromising oncological outcomes. However, tumors located in the upper inner quadrant (UIQ) are challenging for surgeons because treatment gives rise to visible scars, glandular deformities, and deviation of the nipple-areolar complex. The present study was performed to analyze a modification of the matrix rotation technique for UIQ tumors and address the main drawback of this technique, which is a visible scar on the commonly exposed part of the breast. A prospective database of seven patients who presented with UIQ tumors and underwent the new modification technique was utilized for the analysis. All patients preferred the modified technique over the standard technique because of the absence of a scar in the UIQ (visible breast line). The postoperative patient-reported outcomes regarding breast shape, breast symmetry, and scar location were also satisfactory. No surgical complications were reported. This modified surgical technique results in a scarless UIQ and is an aesthetically acceptable procedure that can be considered for UIQ tumors.
Patients aged between 2 months and 18 years with temporary central venous catheter in the pediatric intensive care unit were recruited. Patients younger than 2 months of age, patients with a catheter use of less than 48 hours, patients with a history of allergic reaction with chlorhexidine, patients with a skin condition that interferes with skin cleansing with chlorhexidine, and immunocompromised patients were excluded from the study. Participants of the study were randomized with a ratio of 1:1. In study group, standard bathing will be applied on the first day of insertion of the central venous catheter, and in addition to that it is planned to clean the skin of the patient daily with cleaning pads impregnated with 2% Chlorhexidine gluconate.
Neurodegenerative disorders are the main cause of cognitive and physical disabilities, affect millions of people worldwide, and their incidence is on the rise. Emerging evidence pinpoints a disturbance of the communication of the gut-brain axis, and in particular to gut microbial dysbiosis, as one of the contributors to the pathogenesis of these diseases. In fact, dysbiosis has been associated with neuro-inflammatory processes, hyperactivation of the neuronal immune system, impaired cognitive functions, aging, depression, sleeping disorders, and anxiety. With the rapid advance in metagenomics, metabolomics, and big data analysis, together with a multidisciplinary approach, a new horizon has just emerged in the fields of translational neurodegenerative disease. In fact, recent studies focusing on taxonomic profiling and leaky gut in the pathogenesis of neurodegenerative disorders are not only shedding light on an overlooked field but are also creating opportunities for biomarker discovery and development of new therapeutic and adjuvant strategies to treat these disorders. Lactiplantibacillus plantarum (LBP) strains are emerging as promising psychobiotics for the treatment of these diseases. In fact, LBP strains are able to promote eubiosis, increase the enrichment of bacteria producing beneficial metabolites such as short-chain fatty acids, boost the production of neurotransmitters, and support the homeostasis of the gut-brain axis. In this review, we summarize the current knowledge on the role of the gut microbiota in the pathogenesis of neurodegenerative disorders with a particular focus on the benefits of LBP strains in Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, autism, anxiety, and depression.
PURPOSE: An artificial microRNA for suppressing expresison or activation of aldehyde dehydrogenaase-2(ALDH-2) is provided to treat and/or prevent alcoholism diseases. CONSTITUTION: An artificial microRNA(amiRNA) suppresses expression or activation of aldehyde dehydrogenase-2(ALDH-2) and has a sequence selected from sequence numbers 1-4. A gene encoding the amiRNA contains a sequence selected from sequence numbers 5-8. A recombinant expression vector contains the gene. The expression vector includes lentivirus vector, retrovirus vector, or adenovirus. A composition for preventing and treating alcoholism diseases contains an inhibitor for expression or activation of ALDH2 as an active ingredient.
Prostate cancer is the 2nd most common malignancy in the world as well as the leading cancer in male population in Taiwan. The treatment selections of prostate cancer are limited by the uncertainty of its aggressiveness (i.e.: histological graded) and staging before treatment. Although prostate mpMRI has much better ability for detection and localization of prostate cancers than other imaging modalities and diagnostic tests, there is still gap for risk stratifications and treatment selection based on prostate mpMRI findings. Thus, a robust radiomics prediction models based on imaging biomarkers on prostate mpMRI with high prediction accuracy could fill the gap of misclassification of risk stratifications of prostate cancers, guides treatment selections and providing monitoring schedules for treated patients as well as early timely additional treatments (i.e.: target therapy or immunotherapy) for patients with high risk of early recurrence. Furthermore, radiomics could provide consistent information which help in decreasing interobserver and intra-observer variability of interpretating prostate cancer even in the use of PIRADS. In this way, this would save the fee of inappropriate or ineffective treatment and avoid unnecessary time and cost of monitoring low risk patients as well as improve patients' survivals and possibly life-quality as well.
Gliolan® is presented as a powder for oral solution in 60 ml colorless glass vials. The formulation contains 1.5 g 5-aminolevulinic acid hydrochloride corresponding to 1.17 g of 5-aminolevulinic acid. The oral solution is intended for single (partial) use.
Objective This retrospective study aimed to investigate the association between therapeutic strategies and the development of major cardiac events (MCEs) in intermediate-risk patients by using the the Japanese Assessment of Cardiac Events and Survival Study by Quantitative Gated SPECT (JACCESS) risk model in combination with the stress phase bandwidth (SPBW), an index of left ventricular dyssynchrony. Methods Patients were followed-up for three years to confirm their prognosis. Based on the estimated propensity scores, the patients who underwent revascularization within the first 60 days after SPECT and those who did not were matched 1:1 (n=367 per group). The composite endpoint was the occurrence of MCEs, consisting of cardiac death, non-fatal myocardial infarction, and severe heart failure. SPBW was calculated by a phase analysis using the Heart Risk View-F software program, and the MCE rate was compared between the two groups by applying the normal value of SPBW (38°). Patients The study included 2,053 patients with either known or suspected coronary artery disease who underwent electrocardiogram-gated single-photon emission computed tomography myocardial perfusion imaging and were at intermediate risk of MCE according to the J-ACCESS risk model. Results During follow-up, 54 of the 734 patients (7.4%) experienced MCEs. The overall incidence of MCE in intermediate-risk patients was not significantly different between the two groups. However, the incidence of MCE in patients with an abnormal SPBW was significantly lower in those who underwent early revascularization (4.8% vs. 11.9%, p=0.0407). Conclusion The combination of the J-ACCESS risk model and the SPBW is thus considered to be an optimal treatment strategy for patients at intermediate risk of MCE, and early revascularization may lead to an improved prognosis in intermediate-risk patients with an abnormal SPBW.
This study aims to improve understanding of the anatomy of the deep brain nuclei relevant to deep brain stimulation as well as stereotactic lesioning procedures, including radio frequency, high-focused ultrasound, and radiosurgery. We created interactive, three-dimensional virtual models from cadaveric dissections and radiological segmentation. We used five brain specimens (ten hemispheres) obtained from routine autopsies, prepared according to Klingler's method. Dissections were done from lateral to medial, medial to lateral, and superior to inferior to expose deep brain stimulation targets and adjacent structures. Using photogrammetry, we scanned the specimens to create detailed three-dimensional models. These models were uploaded to an online platform for free global access. Radiological models were also generated from atlas-based regions using the Montreal Neurological Institute template. We produced 16 high-quality cadaveric models at various stages of dissection. These and the radiological models were examined and interacted with through augmented reality and virtual reality headsets. This approach allowed comprehensive visual access to the anatomical structures and delineated their spatial relationships. These three-dimensional models provide detailed anatomical representations that can enhance anatomical orientiation, improve spatial perception, and serve as valuable educational tools for clinicians and students.
PURPOSE:To obtain a therapeutic agent for hepatic diseases containing 16- ketoalisol A or 13,17-epoxyalisol A as an active component. CONSTITUTION:The objective agent for hepatic diseases contains the compound of formula I or formula II as an active component. The compound of formula I or formula II can be produced by extracting TAKUSHA (a drug prepared from bulb of Alisma plantago-aquatica) with chloroform or 60% ethanol and purifying the extract by a stepwise elution with a proper mixed eluent using silica gel chromatography, ODS column chromatography, ODS preparative high-performance liquid chromatography, etc. The eluent is selected from a hydrophobic organic solvent (e.g. hexane, benzene, chloroform and ethyl acetate), a hydrophilic organic solvent (e.g. acetone, n-butanol and ethanol) and water, and mixing the components at specific ratios. The drug is administered by oral administration at a daily dose of 10-600mg in 1-3 divided doses for adult.
Control participants will receive a link to a general website offering study abroad advice (www.studyabroad.com) and will be asked to spend at least 20 to 30 minutes reviewing their institution's study abroad website content, including policies for drinking abroad. This control condition was selected as a form of "treatment as usual" as our conversations with study abroad personnel indicate this is the extent of typical information students receive about alcohol use abroad.
OBJECTIVE: We investigated the associations of sarcopenia alone, overweight or obesity, and sarcopenic overweight or obesity with COVID-19 hospitalization.
METHODS: Participants from the Lifelines COVID-19 cohort who were infected with COVID-19 were included in this study. Sarcopenia was defined as a relative deviation of muscle mass of ≤ -1.0 SD from the sex-specific mean 24-h urinary creatinine excretion. Overweight or obesity was defined as a body mass index ≥ 25 kg/m2. Sarcopenic overweight or obesity was defined as the presence of overweight or obesity and low muscle mass. COVID-19 hospitalization was self-reported. Logistic regression models were used to analyze the associations of sarcopenia alone, overweight or obesity, and sarcopenic overweight or obesity with COVID-19 hospitalization.
RESULTS: Of the 3594 participants infected with COVID-19 and recruited in this study, 173 had been admitted to the hospital. Compared with the reference group, individuals with overweight or obesity and sarcopenic overweight or obesity were 1.78-times and 2.09-times more likely to have been hospitalized for COVID-19, respectively, whereas sarcopenia alone did not increase the risk of COVID-19 hospitalization.
CONCLUSIONS: In this middle-aged population, sarcopenic overweight or obesity elevated the risk of hospitalization for COVID-19 in those infected with COVID-19 more than overweight or obesity alone. These data support the relevance of sarcopenic overweight or obesity as a risk factor beyond the geriatric setting and should be considered in risk stratification in future public health and vaccination campaigns.
The invention relates to the field of medicinal chemistry, discloses a scutellarin derivative, and further discloses a preparation method and application of the scutellarin derivative. The scutellarin derivative is salified through carboxyl of scutellarin and methylamino of meglumine by using an ionic bond. The preparation method comprises the following steps of: adding meglumine into a scutellarin suspension for stirring to form a settled solution; and performing freeze drying to obtain the scutellarin derivative, or concentrating the settled solution to 1/3-1/2 of the original volume under reduced pressure, filtering to obtain a precipitate, and drying the precipitate to obtain the scutellarin derivative. In the method, the pH value is not required to be controlled, and the process is simple. The scutellarin derivative has high water solubility, and the water insolubility of scutellarin is changed. Meanwhile, as proved by a muscle irritation test on a rabbit and medicament stability research, the scutellarin derivative is safer and more stable than other scutellarin salts, and can be used for preparing a medicament for treating heart cerebrovascular diseases.
Macrophages within the tumor microenvironment, also called tumor associated macrophages (TAMs) have been shown to play a major role in the growth and spread of many types of cancer. Cancer cells produce cytokines that cause the macrophages to differentiate into an M2 subtype. We have designed a mannosylated liposome (MAN-LIPs) and successfully showed it to accumulate in TAMs in a mouse model of pulmonary adenocarcinoma. These liposomes are loaded with  64 Cu to allow tracking by PET imaging, and contain a fluorescent dye in the lipid bilayer permitting subsequent fluorescence microscopy. MAN-LIPs are a promising new vehicle for the delivery of imaging agents to lung TAMs. In addition to imaging, they hold the potential for delivery of therapeutic agents to the tumor microenvironment.
Expansion cohorts of DF6215 in multiple dose levels after evaluation for safety in the DF6215 Dose Escalation arm. Additional Pharmacokinetic (PK) and Pharmacodynamic (PD) samples included in this arm.
Objective: To explore the validity of the Chinese version of tinnitus handicap inventory (THI-CM) using confirmatory factor analysis. Methods: A cross-sectional study was carried out. The patients who complained of tinnitus and visited the Department of Otolaryngology, Head and Neck Surgery at West China Hospital of Sichuan University from March 15 to June 28, 2023 were included. All participants underwent pure tone audiometry and acoustic impedance testing before filling out THI-CM, and the results were subjected to confirmatory factor analysis. Results: A cross-sectional study was carried out. A total of 300 patients aged (47±13) years participated in this study. There were 175 females (58.3%) and 125 males (41.7%). The confirmatory factor analysis showed that χ2/df was 1.597<3.00, root mean square error of approximation (RMSEA) was 0.039<0.05, and standardized root mean square residual (SRMR) was 0.091>0.08. The incremental fit index (IFI), Tucker-Lewis index (TLI), comparative fit index (CFI), and goodness of fit index (GFI) were 0.960, 0.954, 0.960, and 0.902, respectively. The overall model fitted well. Except for one item with a load of 0.493, the load values of the other items were between 0.553 and 0.771. The composite reliability (CR) values of the three dimensions of the scale were between 0.769 and 0.901 (all CR>0.7). The average variance extracted (AVE) values ranged from 0.403 to 0.505 (all AVE<0.7), indicating poor convergent validity of the scale. The square value of AVE in each dimension of the scale was smaller than the correlation coefficient between factors, indicating poor discriminant validity of the scale. Conclusions: The THI-CM has good structural validity, which can be used as an effective tool to evaluate the overall severity of tinnitus. However, its convergent validity and discriminant validity are poor.
STUDY OBJECTIVE: In girls born with an anorectal malformation (ARM), anatomical gynecological anomalies (GA) may be present and might need treatment. Therefore, the aim of this study was to provide an overview of GA in girls born with ARM in our cohort. Additionally, diagnostic timing and methods for GA were assessed.
METHODS: A retrospective mono-center study was performed from January 2000 to December 2022. All patients assigned female at birth were eligible for inclusion. GA were classified according to ESHRE/ESGE classification. Outcomes were the number of girls with GA with subsequent screening methods, factors associated with GA, and GA requiring treatment. Uni- and multivariable logistic regression analyses were performed to identify the association between baseline characteristics and the presence of GA.
RESULTS: In total, 128 girls were included, of whom 30 (24.1%) had additional GA, with vaginal anomalies being present most often (n = 17). Fifty-six patients (43.8%) underwent full screening, and this number improved over time (37.7% before 2018 vs 72.7% after 2018; P = .003). Thirteen of 30 patients (43.3%) required surgical treatment for their GA, without the occurrence of postoperative complications.
CONCLUSION: Additional GA were present in almost a quarter of the girls born with an ARM, with vaginal anomalies most often identified. Despite GA being most often found in patients with cloacal malformations, these anomalies were also identified in patients with other ARM types. Surgical treatment was required in almost half of the girls with GA. Therefore, this study emphasizes the importance of screening for GA in patients with an ARM, regardless of the ARM type.
The purpose of this study is to determine the difference between efffects of KInesio taping combined with traditional physical versus physical therapy alone.

The individual of Age 20-40 years among both genders and are diagnosed cases of plantar fasciitis Pain levels will be assessed using the Numeric Pain Rating Scale (NPRS). ROM will be assessed through goniometry. Gait parameters will be assessed through 30 meter walk test. Participants of interest would be approached and explained about the research. Informed written consent will be taken. It is a single-blinded study and randomization will be done through coin toss method. Both groups will receive conventional intervention. Additionally, Group B will receive kinesio taping treatment. Baseline and post intervention scores would be recorded for both groups.
PURPOSE: A human cancer suppressor gene, a protein encoded thereby, an expression vector containing the same gene, and a cell transformed by the same vector are provided. The gene is useful for prevention and treatment of human cancer. CONSTITUTION: A human cancer suppressor gene HCCS-4 has the nucleotide sequence of SEQ ID NO: 1, wherein the cancer is selected from cervical cancer, liver cancer, kidney cancer, placenta cancer, thymus cancer, spleen cancer, skeletal muscle cancer, and heart cancer. A protein encoded by the human cancer suppressor gene HCCS-4 has the amino acid sequence of SEQ ID NO: 2. An expression vector containing the human cancer suppressor gene HCCS-4 is provided. A cell transformed by the expression vector is Escherichia coli DH5alpha/HCCS-4/pCEV-LAC(KCTC 10178BP).
Subjects with with HFpEF with exercise induced dyspnea (difficult or labored breathing) without clinical symptoms at rest (e.g. peripheral edema, weight gain, and abdominal distention) will receive an oral and injected placebo followed by a 1 week washout period.
We intent to enroll 30 patients who are HBV negative but received HBcAb+ liver. Antiviral treatment with TAF(25mg/d,oral) will be started on the first day after liver transplantation. Post-operative HBV infection is defined with positive HBV marker (HBsAg) and/or positive HBV DNA after liver transplantation. Primary outcome will be evaluated at 48 weeks. All the patients will be followed up for another at least 1 year to evaluate the long term efficacy and safety of TAF.

The primary endpoint is to calculate de novo HBV infection after liver transplantation when treating with TAF. Secondary endpoint is to evaluate the renal safety of TAF after liver transplantation.